39695-96-0

Usage

Type of compound

Salt of 2-(4-nitrophenyl)ethanimidamide

Uses

Synthesis of various pharmaceutical and agricultural products

Receptor antagonism

Potent and selective antagonist of the dopamine D3 receptor

Potential treatment

Various neurological disorders such as Parkinson's disease and schizophrenia

Use in synthesis

Building block in the synthesis of various organic compounds

Locations

Research laboratories and chemical manufacturing facilities

InChI:InChI=1/C8H9N3O2.ClH/c9-8(10)5-6-1-3-7(4-2-6)11(12)13;/h1-4H,5H2,(H3,9,10);1H

Upstream product

• 555-21-5 4-Nitrophenylacetonitrile 
• 75584-64-4 ethyl 2-(4-nitrophenyl)acetimidate hydrochloride 

Downstream Products

• 780763-91-9 [4,6-dihydroxy-2-(4-nitrobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 862186-34-3 methyl [4-hydroxy-2-(4-nitrobenzyl)pyrimidin-5-yl]acetate 
• 780765-24-4 methyl [4-methyl-2-[4-(2-naphthoylamino)benzyl]-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 
• 1362050-48-3 methyl [4-chloro-2-{4-[(4-chlorobenzoyl)(methyl)amino]benzyl}-6-(dimethylamino)-5-pyrimidinyl]acetate 
• 1362050-56-3 methyl {4-(dimethylamino)-2-[4-(2-naphthoylamino)benzyl]-5-pyrimidinyl}acetate 
• 780765-23-3 methyl [4-methyl-2-(4-nitrobenzyl)-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 
• 1362050-35-8 methyl [2-(4-aminobenzyl)-4-methyl-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 
• 780763-93-1 methyl [4-chloro-6-(dimethylamino)-2-(4-nitrobenzyl)-5-pyrimidinyl]acetate 
• 780765-12-0 methyl {4-chloro-6-(dimethylamino)-2-[4-(methylamino)benzyl]-5-pyrimidinyl}acetate 
• 780763-94-2 methyl [2-(4-aminobenzyl)-4-chloro-6-(dimethylamino)-5-pyrimidinyl]acetate 
• 780765-22-2 methyl [4-chloro-6-methyl-2-(4-nitrobenzyl)-5-pyrimidinyl]acetate 
• 780764-81-0 methyl [2-(4-aminobenzyl)-4,6-dichloro-5-pyrimidinyl]acetate 
• 780764-64-9 methyl [2-(4-aminobenzyl)-4-(dimethylamino)-5-pyrimidinyl]acetate 
• 1214271-89-2 [4,6-bis([(2H)6]dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid 

Relevant academic research and scientific papers

ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

Provided herein are 2H- and 13C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical compositions and methods using the 2H- and 13C-enriched compounds, useful for treating CRTH2-related diseases or disorders such as, for example, asthma, allergic rhinitis, atopic dermatitis, allergic conjuvatitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.

Two new types of π-conjugation between a fullerene sphere and an addend

Diazirine addition reactions to C60, followed by an HCl elimination step, yielded [6,6] and [5,6] sp2 carbon bridged fullerenes. The [5,6] adducts (alkylidenehomofullerenes) are the first examples of fullerene structures where the ad

IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES

The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has

Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

The present invention relates to a pyrimidinylacetic acid derivative of formula (1) wherein R1-R4 is defined herein, and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as ashtma, allergic rhinitis and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; and basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals.